Human Regenerative Technologies
Human Regenerative Technologies, LLC is a U.S. biologics company that processes and distributes human amniotic and placental tissue allografts via its proprietary HydraTek® Process, selling directly to hospitals, surgical centers, and wound care clinics across seven U.S. states and Canada.
- Company typePrivate
- Founded2013
- HeadquartersEl Segundo, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Human Regenerative Technologies does
Human Regenerative Technologies, LLC (HRT®) is a U.S.-based biologics company founded in 2013 and headquartered in El Segundo, California. The company specializes in processing and distributing human amniotic and placental tissue allografts under Section 361 of the Public Health Service Act and 21 CFR Part 1271. Since December 31, 2018 it has operated as a majority-owned subsidiary of Skye Biologics Holdings, LLC, serving as the primary allograft tissue processor for Skye Orthobiologics' placental and amniotic tissue product offering. HRT reports over 250,000 cumulative implants and a management team with more than 50 years of combined experience in the 361 tissue allograft space.
HRT's core technology is the proprietary HydraTek® Process, which the company positions as a differentiated tissue processing method that preserves placental tissue in its natural hydrated state and improves handling and delivery characteristics for clinical use. The product portfolio is organized around wound care applications and extends into surgical soft tissue repair and orthopedic use cases, targeting hospitals, ambulatory surgical centers, and wound care clinics. The company is accredited by the American Association of Tissue Banks (AATB), registered with the FDA, and holds tissue bank licenses in California, New York, Maryland, Oregon, Delaware, and Illinois, with additional licensure in Canada.
HRT's business model is a direct B2B field-sales motion selling per-product and per-procedure allograft units to healthcare institutions, with marketing concentrated at orthopedic, foot and ankle, and wound care conferences (AAOS, ACFAS, SAWC). No headcount, revenue, valuation, or funding data are publicly disclosed; pricing is not published and is negotiated through institutional procurement channels.
Human Regenerative Technologies firmographics
Firmographics- Name
- Human Regenerative Technologies
- Legal name
- Human Regenerative Technologies, LLC
- Website
- https://humantissue.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Human Regenerative Technologies, LLC is a U.S. biologics company that processes and distributes human amniotic and placental tissue allografts via its proprietary HydraTek® Process, selling directly to hospitals, surgical centers, and wound care clinics across seven U.S. states and Canada.
- Ownership category
- akta.pro rank
Human Regenerative Technologies industry classification
Industry- Product category
- Tissue Allografts
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
- akta.pro secondary industries
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
Keywords
Where Human Regenerative Technologies is headquartered
LocationHeadquarters
- HQ city
- El Segundo
- HQ country
- United States
- HQ region
- North America
Markets served
Human Regenerative Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Amniotic & Placental Allograft Products: HRT generates revenue through the sale of human amniotic and placental tissue allografts, including wound care and soft tissue products derived from placental connective tissues. Revenue is generated on a per-implant/product transaction basis rather than a recurring subscription model.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Human Regenerative Technologies product offering
Product offeringCore offering
Human Regenerative Technologies processes and distributes human amniotic and placental tissue allografts for medical applications, primarily wound care and soft tissue repair. Products are manufactured using the proprietary HydraTek® Process, which preserves placental and amniotic tissue in its natural hydrated state to maintain tissue integrity and function. All allografts are regulated under Section 361 of the PHS Act and 21 CFR Part 1271.
Product overview
Human Regenerative Technologies (HRT®) offers a unified portfolio of human amniotic and placental tissue allografts for medical applications. The core offering centers on the proprietary HydraTek® Process technology, which processes and preserves placental tissues in their natural hydrated state. Products include wound care applications derived from amniotic and placental tissues. All products are regulated under 361 of the PHS Act and 21 CFR Part 1271 as human cell, tissue, and cellular and tissue-based products (HCT/Ps).
Differentiator
Problem solved
Functional benefit
Brands
- HydraTek®: Revolutionary technology and processing method for harvesting and preserving placenta tissue in its natural hydrated state for use as transplant allografts.
Products and services
- Wound Care Allografts Human amniotic and placental tissue allografts designed for wound care applications, processed using the proprietary HydraTek® technology to preserve tissue in its natural hydrated state. Sold to hospitals, surgical centers, and wound care clinics for patient wound care management.
Quantifiable outcome
- Over 250,000 implants performed to date
Companies that use Human Regenerative Technologies
Customer profileSegments2 records
Ideal customer profiles2 records
Human Regenerative Technologies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Human Regenerative Technologies partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Human Regenerative Technologies competitors and assessment
Company assessmentDirect peers
- AlloSource: AlloSource is a non-profit tissue bank that processes and distributes allografts including amniotic and placental products, directly comparable as a tissue processor serving wound care and orthopedic surgeons.
- MiMedx Group: MiMedx develops and markets amniotic membrane tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications, directly overlapping with HRT's placental/amniotic allograft portfolio and customer base.
- Organogenesis: Organogenesis manufactures and sells biologic skin substitutes and wound care products (Apligraf, Dermagraft, PuraPly), competing with HRT in the advanced wound care and regenerative tissue segment.
Broad incumbents
- Smith+Nephew: Smith+Nephew offers a broad portfolio of advanced wound care and orthobiologics products, including placental-derived grafts through its Osiris heritage, overlapping with HRT's wound and orthopedic indications.
- Coloplast: Coloplast's wound care division offers a range of advanced dressings and biologic wound therapies, positioning it as a broad incumbent competitor in the wound care channels HRT serves.
- ConvaTec: ConvaTec provides advanced wound care and skin substitute products (e.g., Avelle, InnovaMatrix) targeting similar hospitals and wound clinics as HRT.
- Arthrex: Arthrex is a large orthopedic surgical device company with an expanding orthobiologics portfolio that overlaps with HRT's orthopedic and soft tissue repair use cases.
- Integra LifeSciences: Integra LifeSciences is an established medical device company with a sizeable regenerative wound care portfolio (Integra Dermal Regeneration Template, amniotic products) that competes with HRT across wound care and surgical soft tissue repair.
Emerging players
- Celularity: Celularity develops placental-derived and cellular regenerative products for wound care and orthopedics, representing an emerging competitor with overlapping science and indication focus to HRT.
- Amniox Medical: Amniox Medical markets amniotic membrane-based products (CLARIX, NEOX) for wound healing and surgical applications, an emerging niche player directly overlapping with HRT's placental allograft focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Human Regenerative Technologies social profiles
Digital presenceHuman Regenerative Technologies compliance and trust
Trust signalCompliance3 records
Human Regenerative Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Human Regenerative Technologies leadership team
Management profileNumber of profiles
Human Regenerative Technologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Human Regenerative Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Human Regenerative Technologies
What does Human Regenerative Technologies do?
Human Regenerative Technologies processes and distributes human amniotic and placental tissue allografts for medical applications, primarily wound care and soft tissue repair. Products are manufactured using the proprietary HydraTek® Process, which preserves placental and amniotic tissue in its natural hydrated state to maintain tissue integrity and function. All allografts are regulated under Section 361 of the PHS Act and 21 CFR Part 1271.
Is Human Regenerative Technologies a public or private company?
Human Regenerative Technologies is a private company. It is classified as corporate owned and is currently operating.
When was Human Regenerative Technologies founded?
Human Regenerative Technologies was founded in 2013. It employs 1 to 10 people.
Where is Human Regenerative Technologies based?
Human Regenerative Technologies is headquartered in El Segundo, United States, in the North America region.
How does Human Regenerative Technologies make money?
One revenue line is on record: amniotic & Placental Allograft Products.
Who are Human Regenerative Technologies's main competitors?
Direct peers on record are AlloSource, MiMedx Group and Organogenesis. Broad incumbents are Smith+Nephew, Coloplast, ConvaTec, Arthrex and Integra LifeSciences. Emerging players are Celularity and Amniox Medical.
Does Human Regenerative Technologies have an API?
No public API is recorded for Human Regenerative Technologies.
What industry is Human Regenerative Technologies in?
Human Regenerative Technologies's product category is Tissue Allografts. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.